ValiPharma
Therapeutics division with a promising cancer treatment in development.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
€290k | Grant | ||
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | - | - | - | 418 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | - | - | - | (21295 %) | (3741 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | - | - | - | (21226 %) | (3849 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | - | - | - | 3993 % | 493 % |
Source: Company filings or news article
Related Content
ValiRx is a clinical-stage biotechnology company focused on the development of therapeutics for cancer and women's health. The company was founded in 2000 and is headquartered in London, United Kingdom. ValiRx operates with a model of in-licensing early-stage drug candidates, adding value through pre-clinical and clinical development, and then seeking partners for further development and commercialization.
The company's main therapeutic focus is on oncology, with a pipeline that includes VAL201 for prostate cancer and other solid tumors, which has completed a Phase I/II clinical trial. Another key project is VAL301, being developed for endometriosis, a condition affecting women's health. Additionally, ValiRx has a preclinical program, VAL401, which reformulates an existing drug for the treatment of lung cancer and other oncology indications. The company has also established a joint venture with Ambrose Healthcare to form a women's health company called Aeterna, and it has a service-based subsidiary, Inaphaea BioLabs, which provides services to external clients.
ValiRx is led by CEO Dr. Suzanne Dilly. The company's strategy aims to de-risk drug development by taking projects through the challenging early stages of clinical trials before partnering with larger pharmaceutical companies. This business model allows them to manage risk while advancing a diverse portfolio of treatments. ValiRx is publicly traded on the AIM market of the London Stock Exchange under the ticker VAL.
Keywords: biotechnology, oncology, therapeutics, drug development, clinical trials, prostate cancer, women's health, endometriosis, cancer treatment, AIM-listed
